Amneal Pharmaceuticals (AMRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $19.18, -0.36% vs the prior close of $19.25.
- Volume 2.29M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AMRX dips 0.4% to $19.18. Closed at $19.18, -0.36% vs the prior close of $19.25. Day range $18.94–$19.39, opened at $19.28.
AMRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AMRX dips 0.4% to $19.18
- Closed at $19.18, -0.36% vs the prior close of $19.25. Day range $18.94–$19.39, opened at $19.28.
- Volume was 2.29M shares, 0.9x its 50-day average of 2.59M.
- Price is +3.3% vs its 50-day average ($18.56) and +24.9% vs its 200-day average ($15.36).
- 52-week range $9.75–$21.17; today's close sits at 83% of that range, 9.4% below the 52-week high.
Oct 15, 2026 — AMRX rises 1.9% to $19.25
- Closed at $19.25, +1.85% vs the prior close of $18.90. Day range $18.78–$19.78, opened at $18.96.
- Volume was 4.45M shares, 1.8x its 50-day average of 2.54M.
- Price is +3.8% vs its 50-day average ($18.54) and +25.6% vs its 200-day average ($15.32).
- 52-week range $9.56–$21.17; today's close sits at 83% of that range, 9.1% below the 52-week high.
Oct 14, 2026 — AMRX slides 3.4% to $18.90
- Closed at $18.90, -3.42% vs the prior close of $19.57. Day range $18.85–$19.93, opened at $19.49.
- Volume was 3.96M shares, 1.6x its 50-day average of 2.51M.
- Price is +2.0% vs its 50-day average ($18.53) and +23.6% vs its 200-day average ($15.29).
- 52-week range $9.56–$21.17; today's close sits at 80% of that range, 10.7% below the 52-week high.
Oct 13, 2026 — AMRX dips 2.3% to $19.57 on 2.0x normal volume
- Closed at $19.57, -2.30% vs the prior close of $20.03. Day range $19.45–$20.15, opened at $20.05.
- Volume was 5.00M shares, 2.0x its 50-day average of 2.46M — unusually heavy trading.
- Price is +5.7% vs its 50-day average ($18.52) and +28.2% vs its 200-day average ($15.26).
- 52-week range $9.56–$21.17; today's close sits at 86% of that range, 7.6% below the 52-week high.
Oct 12, 2026 — AMRX rises 0.6% to $20.03 on 1.9x normal volume
- Closed at $20.03, +0.60% vs the prior close of $19.91. Day range $19.86–$20.28, opened at $20.04.
- Volume was 4.59M shares, 1.9x its 50-day average of 2.40M — unusually heavy trading.
- Price is +8.3% vs its 50-day average ($18.50) and +31.5% vs its 200-day average ($15.23).
- 52-week range $9.56–$21.17; today's close sits at 90% of that range, 5.4% below the 52-week high.
Oct 9, 2026 — AMRX rises 1.3% to $19.91
- Closed at $19.91, +1.32% vs the prior close of $19.65. Day range $19.53–$19.93, opened at $19.59.
- Volume was 2.09M shares, 0.9x its 50-day average of 2.41M.
- Price is +7.8% vs its 50-day average ($18.47) and +31.0% vs its 200-day average ($15.19).
- 52-week range $9.56–$21.17; today's close sits at 89% of that range, 6.0% below the 52-week high.
Oct 8, 2026 — AMRX ends flat (+0.0%) to $19.65, 3 down days in a row
- Closed at $19.65, +0.00% vs the prior close of $19.65. Day range $18.97–$19.72, opened at $19.65.
- Volume was 3.24M shares, 1.4x its 50-day average of 2.39M.
- Price is +6.6% vs its 50-day average ($18.44) and +29.6% vs its 200-day average ($15.16).
- 52-week range $9.56–$21.17; today's close sits at 87% of that range, 7.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — AMRX slides 3.2% to $19.65 on 2.0x normal volume
- Closed at $19.65, -3.18% vs the prior close of $20.30. Day range $19.53–$20.53, opened at $20.24.
- Volume was 4.66M shares, 2.0x its 50-day average of 2.33M — unusually heavy trading.
- Price is +6.6% vs its 50-day average ($18.43) and +29.9% vs its 200-day average ($15.12).
- 52-week range $9.56–$21.17; today's close sits at 87% of that range, 7.2% below the 52-week high.
Oct 6, 2026 — AMRX ends flat (-0.3%) to $20.30
- Closed at $20.30, -0.27% vs the prior close of $20.35. Day range $20.00–$20.60, opened at $20.53.
- Volume was 3.59M shares, 1.6x its 50-day average of 2.28M.
- Price is +10.2% vs its 50-day average ($18.41) and +34.5% vs its 200-day average ($15.09).
- 52-week range $9.56–$21.17; today's close sits at 92% of that range, 4.2% below the 52-week high.
Oct 5, 2026 — AMRX ends flat (+0.2%) to $20.35
- Closed at $20.35, +0.25% vs the prior close of $20.30. Day range $20.23–$20.59, opened at $20.43.
- Volume was 3.91M shares, 1.8x its 50-day average of 2.23M.
- Price is +10.8% vs its 50-day average ($18.37) and +35.2% vs its 200-day average ($15.05).
- 52-week range $9.56–$21.17; today's close sits at 93% of that range, 3.9% below the 52-week high.
Oct 2, 2026 — AMRX rises 1.1% to $20.30
- Closed at $20.30, +1.15% vs the prior close of $20.07. Day range $20.00–$20.54, opened at $20.19.
- Volume was 2.82M shares, 1.3x its 50-day average of 2.22M.
- Price is +10.8% vs its 50-day average ($18.32) and +35.3% vs its 200-day average ($15.01).
- 52-week range $9.56–$21.17; today's close sits at 92% of that range, 4.1% below the 52-week high.
AMRX latest news & SEC filings
Every SEC filing by or about AMRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Buchi J Kevin gifted 20,445 shares on Sep 17, 2026; now holds 75,077
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kiely John sold 50,000 shares at $17.64 (≈$882.00K) on Aug 13, 2026
- Kiely John sold 50,000 shares at $17.64 (≈$882.00K) on Aug 13, 2026
- Kiely John sold 50,000 shares at $17.64 (≈$882.00K) on Aug 13, 2026
- Kiely John sold 50,000 shares at $17.64 (≈$882.00K) on Aug 13, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shah Nikita sold 146,403 shares at $17.51 (≈$2.56M) on Aug 12, 2026
- Shah Nikita sold 146,403 shares at $17.51 (≈$2.56M) on Aug 12, 2026
- Shah Nikita sold 146,403 shares at $17.51 (≈$2.56M) on Aug 12, 2026
- Shah Nikita sold 146,403 shares at $17.51 (≈$2.56M) on Aug 12, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $796.20M (prior year $724.51M) (+9.9% vs Jun 30, 2025)
- Net income: $57.66M (prior year $22.42M) (+157.2% vs Jun 30, 2025)
- Diluted EPS: $0.18 (prior year $0.07) (+157.1% vs Jun 30, 2025)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jul 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jul 30, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Things to know before you trade AMRX
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Apr 22, 2026, Feb 27, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.75% (largest 7.7%).
- Liquidity: about 3.55M shares (≈$68.11M) trade per day on average.
- 52-week position: $19.18 vs a range of $9.75–$21.17 (83% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: John Kiely sold 50,000 shares on Aug 13, 2026.
- Latest filings: 8-K Aug 10, 2026; 10-Q Aug 6, 2026; 8-K Aug 3, 2026.
- Share count: 319.35M shares outstanding (Jul 31, 2026), +1.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AMRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 19.28 | 19.39 | 18.94 | 19.18 | 2.29M |
| Oct 15, 2026 | 18.96 | 19.78 | 18.78 | 19.25 | 4.45M |
| Oct 14, 2026 | 19.49 | 19.93 | 18.85 | 18.90 | 3.96M |
| Oct 13, 2026 | 20.05 | 20.15 | 19.45 | 19.57 | 5.00M |
| Oct 12, 2026 | 20.04 | 20.28 | 19.86 | 20.03 | 4.59M |
| Oct 9, 2026 | 19.59 | 19.93 | 19.53 | 19.91 | 2.09M |
| Oct 8, 2026 | 19.65 | 19.72 | 18.97 | 19.65 | 3.24M |
| Oct 7, 2026 | 20.24 | 20.53 | 19.53 | 19.65 | 4.66M |
| Oct 6, 2026 | 20.53 | 20.60 | 20.00 | 20.30 | 3.59M |
| Oct 5, 2026 | 20.43 | 20.59 | 20.23 | 20.35 | 3.91M |
| Oct 2, 2026 | 20.19 | 20.54 | 20.00 | 20.30 | 2.82M |
| Oct 1, 2026 | 20.13 | 20.26 | 19.61 | 20.07 | 3.94M |
| Sep 30, 2026 | 20.29 | 20.50 | 19.98 | 20.14 | 4.10M |
| Sep 29, 2026 | 20.43 | 20.78 | 20.06 | 20.20 | 2.85M |
| Sep 28, 2026 | 19.55 | 20.62 | 19.42 | 20.50 | 2.99M |
| Sep 25, 2026 | 20.00 | 20.00 | 19.33 | 19.77 | 2.88M |
| Sep 24, 2026 | 19.29 | 19.86 | 19.19 | 19.81 | 1.70M |
| Sep 23, 2026 | 19.70 | 20.17 | 18.74 | 19.33 | 3.58M |
| Sep 22, 2026 | 20.00 | 20.01 | 19.14 | 19.50 | 2.48M |
| Sep 21, 2026 | 18.96 | 21.17 | 18.77 | 20.16 | 5.91M |
About Amneal Pharmaceuticals
Amneal Pharmaceuticals (AMRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Fiscal year ends December 31. SEC CIK 1723128.
AMRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Deborah M. Autor | Director | May 12, 2026 |
| J Kevin Buchi | Director | Sep 21, 2026 |
| Jeffrey P. George | Director | May 8, 2026 |
| John Kiely | Director | Aug 14, 2026 |
| Paul M Meister | Director | May 8, 2026 |
| Ted C Nark | Director | May 8, 2026 |
| Chintu Patel | Co-CEO | Aug 12, 2026 |
| Chirag K. Patel | President & Co-CEO | Aug 12, 2026 |
| Gautam Patel | Director | Aug 12, 2026 |
| Shlomo Yanai | Director | May 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Andrew S Boyer | Executive Vice President | Sep 2, 2026 |
| Jason B. Daly | EVP, Chief Legal Officer | Aug 13, 2026 |
| Tasos Konidaris | Executive Vice President & CFO | Mar 5, 2026 |
| Chintu Patel | Co-CEO | Aug 12, 2026 |
| Chirag K. Patel | President & Co-CEO | Aug 12, 2026 |
| Nikita Shah | Executive Vice President | Aug 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 13, 2026 | John Kiely | Sale | 50,000 | $17.64 |
| Aug 13, 2026 | John Kiely | Sale | 50,000 | $17.64 |
| Aug 13, 2026 | John Kiely | Sale | 50,000 | $17.64 |
| Aug 13, 2026 | John Kiely | Sale | 50,000 | $17.64 |
| Aug 12, 2026 | Nikita Shah | Sale | 146,403 | $17.51 |
| Aug 12, 2026 | Nikita Shah | Sale | 146,403 | $17.51 |
| Aug 12, 2026 | Nikita Shah | Sale | 146,403 | $17.51 |
| Aug 12, 2026 | Nikita Shah | Sale | 146,403 | $17.51 |
| Aug 12, 2026 | Jason B. Daly | Sale | 210,000 | $17.40 |
| Aug 12, 2026 | Jason B. Daly | Sale | 210,000 | $17.40 |
| Aug 12, 2026 | Jason B. Daly | Sale | 210,000 | $17.40 |
| Aug 12, 2026 | Jason B. Daly | Sale | 210,000 | $17.40 |
| Aug 11, 2026 | Jason B. Daly | Sale | 6,613 | $17.70 |
| Aug 11, 2026 | Jason B. Daly | Sale | 6,613 | $17.70 |
| Aug 11, 2026 | Jason B. Daly | Sale | 6,613 | $17.70 |
AMRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $3.02B | $72.06M | 0.22 | $339.99M |
| Dec 31, 2024 | $2.79B | $-116.89M | -0.38 | $295.10M |
| Dec 31, 2023 | $2.39B | $-83.99M | -0.48 | $345.58M |
| Dec 31, 2022 | $2.21B | $-270.58M | -0.86 | $65.10M |
| Dec 31, 2021 | $2.09B | $13.16M | 0.07 | $241.82M |
Latest balance sheet: total assets $3.78B, total liabilities $0, cash $127.64M (as of Jun 30, 2026).
AMRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $18.50 |
| May 7, 2026 | 8-K Item 2.02 (results) | $13.72 |
| Apr 22, 2026 | 8-K Item 2.02 (results) | $12.82 |
| Feb 27, 2026 | 8-K Item 2.02 (results) | $13.81 |
| Jan 13, 2026 | 8-K Item 2.02 (results) | $12.97 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $10.00 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $8.13 |
| Jul 21, 2025 | 8-K Item 2.02 (results) | $7.91 |
| May 2, 2025 | 8-K Item 2.02 (results) | $7.97 |
| Feb 28, 2025 | 8-K Item 2.02 (results) | $8.67 |
| Jan 15, 2025 | 8-K Item 2.02 (results) | $8.22 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $8.73 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AMRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.